Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
iPS Cell Differentiation01:22

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From dysphagia to kidney disease: Alport syndrome with leiomyomatosis.

Kidney international·2026
Same author

Podocin oligomers regulate the ordering of nephrin chains, providing the molecular basis of <i>NPHS2</i> interallelic interactions.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Genetic screening in kidney transplant candidates.

Clinical kidney journal·2026
Same author

Splice modulation of COL4A5 reinstates collagen IV assembly in an organoid model of Alport syndrome.

JCI insight·2025
Same author

Exome Sequencing in a Large Cohort with Ciliopathy-Related Kidney Disease.

Clinical journal of the American Society of Nephrology : CJASN·2025
Same author

Mono-allelic pathogenic variants in JAG1 cause autosomal dominant tubulo-interstitial kidney disease (ADTKD-JAG1).

Kidney international·2025

Related Experiment Video

Updated: Jun 13, 2026

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study
08:00

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study

Published on: April 11, 2018

Cell therapy for cystinosis.

Sara Terryn1, Olivier Devuyst, Corinne Antignac

  • 1Division of Nephrology, Université catholique de Louvain Medical School, B-1200 Brussels, Belgium.

Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association
|April 17, 2010
PubMed
Summary
This summary is machine-generated.

Syngeneic bone marrow cell (BMC) and hematopoietic stem cell (HSC) transplantation effectively reduced cystine accumulation in a mouse model of cystinosis. This therapy shows promise for treating cystinosis and other kidney disorders.

More Related Videos

Purification of the Cystic Fibrosis Transmembrane Conductance Regulator Protein Expressed in Saccharomyces cerevisiae
15:12

Purification of the Cystic Fibrosis Transmembrane Conductance Regulator Protein Expressed in Saccharomyces cerevisiae

Published on: May 10, 2014

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
07:04

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients

Published on: February 11, 2017

Related Experiment Videos

Last Updated: Jun 13, 2026

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study
08:00

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study

Published on: April 11, 2018

Purification of the Cystic Fibrosis Transmembrane Conductance Regulator Protein Expressed in Saccharomyces cerevisiae
15:12

Purification of the Cystic Fibrosis Transmembrane Conductance Regulator Protein Expressed in Saccharomyces cerevisiae

Published on: May 10, 2014

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
07:04

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients

Published on: February 11, 2017

Area of Science:

  • Medical Genetics
  • Lysosomal Storage Diseases
  • Stem Cell Therapy

Background:

  • Cystinosis is an autosomal recessive metabolic disease.
  • Lysosomal cystine accumulation causes multi-organ dysfunction, including kidney failure.
  • Current treatments are limited.

Purpose of the Study:

  • To evaluate bone marrow cell (BMC) and hematopoietic stem cell (HSC) therapy in a mouse model of cystinosis.
  • To assess the impact of transplantation on cystine levels and organ damage.
  • To determine the therapeutic potential of BMC and HSC transplantation for cystinosis.

Main Methods:

  • Used Ctns knock-out (Ctns(-/-)) mice as a model for cystinosis.
  • Performed syngeneic bone marrow cell (BMC) transplantation.
  • Transplanted hematopoietic stem cells (HSCs).

Main Results:

  • BMC transplantation significantly reduced cystine content in all tested tissues.
  • Transplantation attenuated kidney injury progression and corneal cystine crystal formation.
  • Engraftment of donor BMC producing functional cystine transporters correlated with therapeutic effects.
  • HSC transplantation demonstrated similar therapeutic efficacy to BMC transplantation.

Conclusions:

  • Syngeneic BMC and HSC transplantation are effective treatments in a mouse model of cystinosis.
  • This therapy reduces cystine accumulation and mitigates organ damage.
  • BMC or HSC transplantation represents a potential therapeutic strategy for cystinosis and other renal tubular disorders.